Mirum Pharmaceuticals, Inc.
MIRM
Rank in Stocks
#3278
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Share Price
$82.58
Last synced: 2026-10-19
Market Cap
$5.36B
Change (1 day)
3.05%
Change (1 year)
13.08%
Country
US
Trade Mirum Pharmaceuticals, Inc. (MIRM)
Category
Healthcare
Number of shares outstanding for Mirum Pharmaceuticals, Inc. (MIRM)
Number of shares outstanding as of June 2026: 63.37M
According to Mirum Pharmaceuticals, Inc. latest financial reports and stock price the company's current number of shares outstanding is 63.37M. At the end of December 2023 the company had 40.89M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Mirum Pharmaceuticals, Inc. (MIRM) from 2018 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 63.37M | 33.35% |
| 2024 | 47.52M | 16.24% |
| 2023 | 40.89M | 20.82% |
| 2022 | 33.84M | 11.60% |
| 2021 | 30.32M | 20.08% |
| 2020 | 25.25M | 9.84% |
| 2019 | 22.99M | 0.00% |
| 2018 | 22.99M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 300.64% |
US
|
|
| 396.00M | 524.86% |
US
|
|
| 478.91M | 655.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -1.88% |
NL
|
